Molecular Interaction Fields and 3D-QSAR Studies of p53-MDM2 Inhibitors Suggest Additional Features of Ligand-Target Interaction

The design and optimization of small molecule inhibitors of the murine double minute clone 2-p53 (p53-MDM2) interaction has attracted a great deal of interest as a way to novel anticancer therapies. Herein we report 3D-QSAR studies of 41 small molecule inhibitors based on the use of molecular interaction fields and docking experiments as part of an approach to generating predictive models of MDM2 affinity and shedding further light on the structural elements of the ligand-target interaction. These studies have yielded predictive models explaining much of the variance of the 41 compound training set and satisfactorily predicting with 75% success an external test set of 36 compounds. Not surprisingly, and in full agreement with previous data, inspection of the 3D-QSAR coefficients reveals that the major driving force for potent inhibition is given by the hydrophobic interaction between the inhibitors and the p53 binding cleft of MDM2. More surprisingly, and challenging previous suggestions, the projection of the 3D-QSAR coefficients back onto the experimental structures of MDM2 provides an intriguing hypothesis concerning an active role played by the N-terminal region of MDM2 in ligand binding.

[1]  M. Walkinshaw,et al.  The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. , 2010, Journal of molecular biology.

[2]  Jonathan Y. Mane,et al.  Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. , 2010, Journal of molecular graphics & modelling.

[3]  Gabriele Cruciani,et al.  Molecular fields in drug discovery: getting old or reaching maturity? , 2010, Drug discovery today.

[4]  Shanghai Yu,et al.  Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. , 2009, Journal of medicinal chemistry.

[5]  R. Pellicciari,et al.  Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition , 2009, Proteins.

[6]  Ernst Schönbrunn,et al.  Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX* , 2009, The Journal of Biological Chemistry.

[7]  Chong Li,et al.  Apamin as a template for structure-based rational design of potent peptide activators of p53. , 2009, Angewandte Chemie.

[8]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[9]  A. Hopfinger,et al.  The receptor-dependent QSAR paradigm: an overview of the current state of the art. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[10]  M. Walkinshaw,et al.  Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif , 2009, Journal of chemical biology.

[11]  R. Pellicciari,et al.  MDM2/MDMX inhibitor peptide: WO2008106507 , 2009, Expert opinion on therapeutic patents.

[12]  R. V. van Montfort,et al.  Structure-based design of molecular cancer therapeutics. , 2009, Trends in biotechnology.

[13]  A. Dömling Hot, hotter, hottest , 2009, Cell cycle.

[14]  Nir Ben-Tal,et al.  Study of MDM2 Binding to p53-Analogues: Affinity, Helicity, and Applicability to Drug Design , 2009, J. Chem. Inf. Model..

[15]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[16]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[17]  D. Hadjipavlou-Litina,et al.  Chalcones in cancer: understanding their role in terms of QSAR. , 2009, Current medicinal chemistry.

[18]  F. Mancini,et al.  MDM4 (MDMX) and its Transcript Variants , 2009, Current genomics.

[19]  G. Wahl,et al.  Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.

[20]  John A. Robinson,et al.  1 Thermodynamic and Computational Studies on the Binding of p 53-Derived Peptides and Peptidomimetic Inhibitors to HDM 2 , 2009 .

[21]  Gabriele Cruciani,et al.  Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition , 2008, J. Chem. Inf. Model..

[22]  Shubhra Ghosh Dastidar,et al.  Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. , 2008, Journal of the American Chemical Society.

[23]  Peter Gedeck,et al.  Exploiting QSAR models in lead optimization. , 2008, Current opinion in drug discovery & development.

[24]  Small molecule inhibitors of the p53-MDM2. , 2008, Current medicinal chemistry.

[25]  L. M. Espinoza-Fonseca,et al.  Aromatic-aromatic interactions in the formation of the MDM2-p53 complex. , 2008, Biochemical and biophysical research communications.

[26]  Shaomeng Wang,et al.  Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer , 2008, Molecular Cancer Therapeutics.

[27]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[28]  H. Schünemann,et al.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties , 2008, Journal of Molecular Medicine.

[29]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[30]  A. Unterberg,et al.  Uniform MDM 2 Overexpression in a Panel of Glioblastoma Multiforme Cell Lines with Divergent EGFR and p 53 Expression Status , 2008 .

[31]  Mark R Player,et al.  Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. , 2008, Expert opinion on investigational drugs.

[32]  Stephen R. Johnson,et al.  The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy) , 2008, J. Chem. Inf. Model..

[33]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[34]  Deepak Srinivasan,et al.  Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study , 2007, Cell cycle.

[35]  M. Dyer,et al.  Targeting MDM2 and MDMX in retinoblastoma. , 2007, Current cancer drug targets.

[36]  Claudio N. Cavasotto,et al.  Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.

[37]  Ray Luo,et al.  Binding induced folding in p53-MDM2 complex. , 2007, Journal of the American Chemical Society.

[38]  Jürgen Bajorath,et al.  Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. , 2007, Drug discovery today.

[39]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[40]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[41]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[42]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[43]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[44]  J. Trujillo-Ferrara,et al.  Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. , 2006, Biopolymers.

[45]  Per Källblad,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. , 2006, Journal of medicinal chemistry.

[46]  C. Schubert,et al.  Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. , 2006, Journal of the American Chemical Society.

[47]  Gerald M. Maggiora,et al.  On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..

[48]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[49]  R. Nussinov,et al.  Comparison of the human and worm p53 structures suggests a way for enhancing stability. , 2006, Biochemistry.

[50]  John A. Robinson,et al.  Structure – Activity Studies in a Family of b-Hairpin Protein Epitope Mimetic Inhibitors of the p 53 – HDM 2 Protein – Protein Interaction , 2006 .

[51]  Paul N Barlow,et al.  Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. , 2005, Journal of molecular biology.

[52]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[53]  H. Carlson,et al.  Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.

[54]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[55]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[56]  Ajay N. Jain Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[57]  Wolfgang Sippl,et al.  Development of biologically active compounds by combining 3D QSAR and structure-based design methods , 2002, J. Comput. Aided Mol. Des..

[58]  D. Abraham,et al.  QSAR: Hydropathic analysis of inhibitors of the p53–mdm2 interaction , 2001, Proteins.

[59]  C. Renner,et al.  Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.

[60]  P. Furet,et al.  Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.

[61]  Hsiao-Huei Wu,et al.  MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.

[62]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[63]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[64]  C. Arrowsmith,et al.  New insights into p53 function from structural studies. , 1996, Oncogene.

[65]  A. Marchetti,et al.  mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[66]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..

[67]  S. Stass,et al.  The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.

[68]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[69]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[70]  J. Freidman,et al.  Multivariate adaptive regression splines , 1991 .

[71]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.